Abstract |
Immunoglobulin heavy chain translocations (t(IGH@)) are suggested to portend a poor prognosis in chronic lymphocytic leukemia (CLL). To determine the clinical significance of a t(IGH@) on CLL-specific cytogenetic abnormalities, we analyzed the outcomes of 142 CLL patients referred for fluorescence in situ hybridization (FISH) analysis with our standard FISH panel, which includes testing for a t(IGH@). Whereas patients with unfavorable (deletion 17p, deletion 11q) and intermediate ( trisomy 12, normal FISH) cytogenetics with concomitant t(IGH@) had similar median treatment-free survival (TFS) as those without a t(IGH@), patients with deletion 13q (del13q) and a t(IGH@) had significantly worse TFS than those without a t(IGH@): median TFS 4.7 versus 8.0 years, P = 0.03 (hazard ratio 4.21, 95% confidence interval 1.06-16.69 y, P = 0.04 in multivariate analysis after adjusting for age, sex, Rai stage, and white blood cell count). The presence of a t(IGH@) further stratified patients with del13q into two prognostic entities, whereby outcomes of those with coexistent del13q and a t(IGH@) were similar to outcomes of those with high risk cytogenetics. Knowledge of the t(IGH@) status in CLL is therefore of clinical importance, as del13q patients with concomitant t(IGH@) may not retain the previously expected favorable outcome.
|
Authors | Alina S Gerrie, Helene Bruyere, Mary Joyce Chan, Chinmay B Dalal, Khaled M Ramadan, Steven J T Huang, Cynthia L Toze, Tanya L Gillan |
Journal | Cancer genetics
(Cancer Genet)
Vol. 205
Issue 10
Pg. 523-7
(Oct 2012)
ISSN: 2210-7762 [Print] United States |
PMID | 22939229
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier Inc. All rights reserved. |
Chemical References |
- Immunoglobulin Heavy Chains
- Vidarabine
- fludarabine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Cohort Studies
- Cytogenetics
- Disease-Free Survival
- Female
- Humans
- Immunoglobulin Heavy Chains
(genetics)
- Immunophenotyping
- In Situ Hybridization, Fluorescence
- Leukemia, Lymphocytic, Chronic, B-Cell
(genetics, immunology, mortality)
- Male
- Middle Aged
- Prognosis
- Time Factors
- Translocation, Genetic
- Vidarabine
(analogs & derivatives, therapeutic use)
|